Format

Send to

Choose Destination
Joint Bone Spine. 2018 Dec;85(6):747-753. doi: 10.1016/j.jbspin.2018.01.008. Epub 2018 Feb 7.

Gout drugs use and risk of cancer: A case-control study.

Author information

1
College of Medicine Science and Technology, Taipei Medical University, 110 Taipei, Taiwan; International Center for Health Information Technology, Taipei Medical University, 110 Taipei, Taiwan.
2
International Center for Health Information Technology, Taipei Medical University, 110 Taipei, Taiwan; Department of Population and Quantitative Health Sciences, Case Western Reserve University, United States.
3
International Center for Health Information Technology, Taipei Medical University, 110 Taipei, Taiwan; Graduate Institute of Biomedical Informatics, Taipei Medical University, 110 Taipei, Taiwan.
4
Joint Commission of Taiwan, 110 New Taipei City, Taiwan.
5
International Center for Health Information Technology, Taipei Medical University, 110 Taipei, Taiwan; Master's Program in Global Health and Development Department, College of Public Health, Taipei Medical University, 110 Taipei, Taiwan.
6
College of Medicine Science and Technology, Taipei Medical University, 110 Taipei, Taiwan; International Center for Health Information Technology, Taipei Medical University, 110 Taipei, Taiwan; Department of Dermatology, Taipei Medical University, Wan Fang Hospital, 110 Taipei, Taiwan. Electronic address: jack@tmu.edu.tw.

Abstract

OBJECTIVE:

Firm conclusion about whether short and long-term gout medications use has an impact on cancer risk remain inconclusive. The aim of this study was to investigate the association between gout drugs use and risk of cancer.

METHODS:

We conducted a retrospective longitudinal population-based case-control study in Taiwan. Cases were identified all patients who were aged 20years or above, and had a first time diagnosis of cancers for the period between 2001 and 2011. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated by using conditional logistic regression.

RESULTS:

We examined 601,733 cases and 2,406,932 matched controls. The adjusted odd ratio for any gout drugs use and overall cancer risk was 1.007 (95% CI: 0.994-1.020). There was a significant risk of leukemia (AOR: 1.34, 95% CI: 1.20-1.50), endometrial cancer (AOR: 1.33, 95% CI: 1.12-1.57), non-Hodgkin's (AOR: 1.24, 95% CI: 1.13-1.35), female breast cancer (AOR: 1.21, 95% CI: 1.13-1.29), cervical cancer (AOR: 1.21, 95% CI: 1.07-1.37). However, no association was observed in male group (AOR: 0.97, 95% CI: 0.95-0.98) but female showed a significantly increased risk of cancer at any site (AOR: 1.107, 95% CI: 1.08-1.13).

CONCLUSION:

In summary, our results suggest that gout drugs increase risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer.

KEYWORDS:

Allopurinol; Breast cancer; Cervical cancer; Gout drugs; Pharmacoepidemiology etc.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center